Helix Biopharma Corp. Announces Board Composition Changes

VANCOUVER, BRITISH COLUMBIA - August 14, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, today announced changes to its Board of Directors (the “Board”), effective immediately.

Mr. Janusz Grabski has resigned from Helix’s Board, with immediate effect. Concurrently, the Board has formally appointed Thomas Mehrling, M.D., Ph.D., Helix’s Chief Executive Officer, as a director of the Company, pursuant to the Board nomination right granted to Laevoroc Immunology AG in connection with Helix’s 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.i

Collectively, these changes are intended to ensure that the Board continues to meet Helix’s evolving governance and capital markets requirements and has the composition and experience needed to support the Company’s clinical development and broader corporate objectives.

The Board would like to thank Mr. Grabski for his service and contributions to Helix and wishes him every success in his future endeavors.

About Helix BioPharma

Helix BioPharma Corp. is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The Company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.

Helix BioPharma’s common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, please visit: https://www.helixbiopharma.com/

For more information, please contact:

Helix BioPharma Corp.
789 West Pender Street, Suite 480
Vancouver, BC
V6C 1H2
Tel: +1 857 208 7687
Thomas Mehrling, MD, PhD, Chief Executive Officer
[email protected]

View the original release on www.newmediawire.com

You May Also Be Interested In

• Former Menhaden Vessel F/V Calcasieu Pass Begins Second Life as Artificial Reef Off Delaware
• Goldgroup Advances San Francisco Toward Potential Production Restart
• Next Crypto to Hit $1: The Arithmetic, and the Meme Coin Presale Now at $0.000015